Enterprise Value
154.6M
Cash
43.62M
Avg Qtr Burn
-5.777M
Short % of Float
9.95%
Insider Ownership
0.44%
Institutional Own.
49.77%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OPC1 (Oligodendrocytes) Details Spinal cord injury, Spine disorder | Phase 1/2 Update | |
OpRegen® (RG6501) (RPE Cells) Details Dry eye disease , Age-related macular degeneration | Phase 1/2 Update | |
VAC2 (Dendritic Cells) Details Lung cancer, Non-small cell lung carcinoma, Lung disease | Phase 1 Update |